These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12446425)

  • 1. Multiple myeloma.
    Anderson KC; Shaughnessy JD; Barlogie B; Harousseau JL; Roodman GD
    Hematology Am Soc Hematol Educ Program; 2002; ():214-40. PubMed ID: 12446425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma.
    Dalton WS; Bergsagel PL; Kuehl WM; Anderson KC; Harousseau JL
    Hematology Am Soc Hematol Educ Program; 2001; ():157-77. PubMed ID: 11722983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Myeloma: New Insights and Therapeutic Approaches.
    Anderson KC; Kyle RA; Dalton WS; Landowski T; Shain K; Jove R; Hazlehurst L; Berenson J
    Hematology Am Soc Hematol Educ Program; 2000; ():147-165. PubMed ID: 11701540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of novel therapeutic targets for multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Anderson KC
    J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of myeloma.
    Smith ML; Newland AC
    QJM; 1999 Jan; 92(1):11-4. PubMed ID: 10209667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma--an update on diagnosis and treatment.
    Caers J; Vande broek I; De Raeve H; Michaux L; Trullemans F; Schots R; Van Camp B; Vanderkerken K
    Eur J Haematol; 2008 Nov; 81(5):329-43. PubMed ID: 18637123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia.
    Giles FJ; Keating A; Goldstone AH; Avivi I; Willman CL; Kantarjian HM
    Hematology Am Soc Hematol Educ Program; 2002; ():73-110. PubMed ID: 12446420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
    Koehne G; Giralt S
    Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for multiple myeloma].
    Kosugi H
    Rinsho Ketsueki; 2015 Mar; 56(3):279-88. PubMed ID: 25876781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
    Kyle RA
    Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents.
    Abe M
    Int J Hematol; 2011 Oct; 94(4):307-309. PubMed ID: 21993876
    [No Abstract]   [Full Text] [Related]  

  • 14. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy in multiple myeloma.
    Goldschmidt H; Hegenbart U; Wallmeier M; Moos M; Haas R
    Leukemia; 1997 Dec; 11 Suppl 5():S27-31. PubMed ID: 9436935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone turnover following autologous transplantation in multiple myeloma.
    Clark RE; Fraser WD
    Leuk Lymphoma; 2002 Mar; 43(3):511-6. PubMed ID: 12002753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the treatment of multiple myeloma.
    Kyle RA
    Oncologist; 2001; 6(2):119-24. PubMed ID: 11306723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
    Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD004626. PubMed ID: 23076906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.